Graviton BioScience Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5M
- Investors
-
6
Graviton BioScience General Information
Description
Developer of clinical-stage drugs designed for the treatment of autoimmune, cancer, and other serious diseases. The company is dedicated to engineering and developing therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases, where its other therapeutic compounds play a pivotal role in pathology and offer drug candidates targeting Rho-associated protein kinase, enabling patients to potentially access groundbreaking treatments for a range of debilitating diseases.
Contact Information
Website
www.gravitoncorp.comCorporate Office
- 125 West End Avenue
- Suite 301
- New York, NY 10023
- United States
Corporate Office
- 125 West End Avenue
- Suite 301
- New York, NY 10023
- United States
Graviton BioScience Timeline
Graviton BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 12-Nov-2026 | $5M | Completed | Clinical Trials - Phase 3 | ||
| 3. Early Stage VC (Series B1) | 14-Feb-2024 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 04-Dec-2023 | $64.8M | $68.3M | Completed | Clinical Trials - Phase 2 | |
| 1. Seed Round | 19-Feb-2021 | $3.5M | $3.5M | Completed | Pre-Clinical Trials |
Graviton BioScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series A-1C | ||||||||
| Series A-1B | ||||||||
| Series A-1A | 9,466,507 | $0.000100 | $0.25 | $3.15 | $3.15 | 1x | $3.15 | 22.06% |
| Series A | 866,336 | $0.000100 | $4.04 | $4.04 | 1x | $4.04 | 2.02% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Graviton BioScience Patents
Graviton BioScience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250289807-A1 | Inhibitors of rock2 | Pending | 29-Apr-2022 | ||
| US-20240366604-A1 | Selective inhibitors of rock2 for the treatment of muscular dystrophy | Pending | 28-Apr-2021 |
Graviton BioScience Signals
Graviton BioScience Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deep Future | Venture Capital | Minority | ||
| Innova Capital Partners | Growth/Expansion | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Enavate Sciences | Venture Capital | Minority | ||
| Ovid Therapeutics | Corporation | Minority |
Graviton BioScience Investments (1)
Graviton BioScience’s most recent deal was a Joint Venture with CinRock Pharma. The deal was made on 02-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CinRock Pharma | 02-Nov-2026 | Joint Venture | Drug Discovery |
Graviton BioScience FAQs
-
When was Graviton BioScience founded?
Graviton BioScience was founded in 2020.
-
Where is Graviton BioScience headquartered?
Graviton BioScience is headquartered in New York, NY.
-
What is the size of Graviton BioScience?
Graviton BioScience has 43 total employees.
-
What industry is Graviton BioScience in?
Graviton BioScience’s primary industry is Drug Discovery.
-
Is Graviton BioScience a private or public company?
Graviton BioScience is a Private company.
-
What is Graviton BioScience’s current revenue?
The current revenue for Graviton BioScience is .
-
How much funding has Graviton BioScience raised over time?
Graviton BioScience has raised $98.3M.
-
Who are Graviton BioScience’s investors?
Deep Future, Innova Capital Partners, Cormorant Asset Management, Enavate Sciences, and Ovid Therapeutics are 5 of 6 investors who have invested in Graviton BioScience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process